PI3K
4 articles
Medicinal ChemistryBioorganic & Medicinal Chemistry
Pyrazolopyrimidine scaffold yields dual PI3K/HDAC6 inhibitors active across breast cancer subtypes
- Pairing PI3K and HDAC inhibition on a pyrazolo[3,4-d]pyrimidine core targets crosstalk between the PI3K/AKT pathway and epigenetic dysregulation in breast cancer.
- Lead compound 13k inhibits PI3Kα at sub-micromolar potency and HDAC6 at low-nanomolar potency; pharmacophore modeling, docking and molecular dynamics rationalized the SAR.
- In ER+, HER2+ and triple-negative lines it curbed proliferation, migration and invasion, and triggered apoptosis and G1 arrest; predicted ADMET looked drug-like.
Unlike CUDC-907, which hits class I HDACs plus PI3K, 13k leans on HDAC6, a cleaner and likely better-tolerated profile if the selectivity holds. But I'd want a PI3Kα/β/δ/γ and HDAC1/2/3 panel, plus cellular readouts (p-AKT, acetyl-tubulin versus acetyl-H3) to prove on-target engagement. Cell data in three subtypes with only predicted ADMET means hydroxamate PK and mutagenicity are still untested.
PharmacologyACS Pharmacology & Translational Science
Pseudolaric acids A and B show neuroprotective signals in cells and an AlCl3 Alzheimer's mouse model
- Pseudolaric acids A and B were tested against Aβ25–35-induced PC12 apoptosis and LPS-stimulated BV2 microglia and RAW264.7 macrophages.
- In vitro, anti-apoptotic effects were linked to IRS-1/Akt/GSK-3β signaling and anti-inflammatory effects to NF-κB and miR-155.
- In an AlCl3-induced mouse model, pseudolaric acid B improved spatial learning and memory in the water maze.
Weak translational chain: Aβ25–35 on PC12 cells and an aluminium-chloride mouse are poor predictors of human Alzheimer's, and the authors concede the mechanisms are not confirmed in vivo. Pseudolaric acid B is also a cytotoxic microtubule-destabilising agent, so the window between neuroprotective and toxic exposure, plus any brain penetration data, matters more than another pathway readout. A transgenic model with PK would be the next step.
PharmacologyBiochemical Pharmacology
Natural-product-derived β-carboline D14 curbs glioma by inhibiting SRC
- Starting from a plant alkaloid with known antitumor activity, the authors built a scalable total synthesis and made a series of nineteen analogues; D14 was the most cytotoxic across glioma lines, including patient-derived primary cells.
- Computational screening, dynamics and thermal-shift assays pointed to SRC as the target, with binding near Gln147 and reduced SRC phosphorylation, dampening PI3K/AKT and STAT3 signaling.
- In an orthotopic mouse glioma model, D14 slowed tumor growth without evident organ toxicity.
Nineteen analogues, one winner, and a target call resting mostly on docking, dynamics and a thermal shift: I wouldn't call SRC the mechanism yet. Without kinome selectivity and a Gln147 mutant, this could be polypharmacology. And orthotopic GL261 is forgiving; show brain exposure across the BBB and a real margin over the cytotoxic dose.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Wild-Type-Sparing PI3Kα H1047R Inhibitors Identified from Quinazolinone Series
- Approved PI3Kα inhibitors for HR+/HER2− PIK3CA-mutated breast cancer cause dose-limiting hyperglycemia and other adverse effects linked to inhibition of wild-type PI3Kα.
- Researchers designed a series of tetrasubstituted quinazolin-4(3H)-one compounds intended to selectively inhibit the oncogenic PI3Kα H1047R mutant.
- Selectivity for the mutant enzyme over wild-type PI3Kα is proposed to stem from a slow-on, slow-off binding mechanism.
- Lead compound 34 showed potent, mutant-selective activity in vitro along with a favorable ADME profile.
- In a T47D xenograft mouse model, compound 34 produced significant tumor growth inhibition without affecting blood glucose or serum insulin levels, unlike a benchmark approved PI3Kα inhibitor.
- The authors note that further optimization of compound 34 is needed to lower the efficacious dose and improve tolerability.
Alpelisib's hyperglycemia problem is the elephant in every PI3Kα SAR discussion — it's the reason dose reductions dog that drug in clinic, tracing straight back to wild-type inhibition in normal insulin signaling. A slow-on, slow-off kinetic selectivity mechanism here is more interesting than a static pocket-shape argument: if H1047R's altered conformational dynamics let this quinazolinone linger on mutant enzyme while it washes out of WT, that's a residence-time story I'd want kinITC and washout kinetics to confirm before fully believing. Tetrasubstituted quinazolinones aren't an exotic scaffold to make, which helps for a program needing heavy analoging around that pocket. Clean xenograft efficacy without glucose/insulin perturbation is the proof-of-concept that matters — but the authors' own admission that compound 34 needs a lower efficacious dose and better tolerability is the real tell: promising probe, not yet a candidate.